Loading clinical trials...
Loading clinical trials...
Safety and Efficiency Study of ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Conditions
Interventions
ET019003-T Cells
Locations
1
China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Start Date
June 12, 2019
Primary Completion Date
July 1, 2021
Completion Date
July 1, 2022
Last Updated
November 12, 2021
NCT06311227
NCT07388563
NCT06263491
NCT06285890
NCT06337318
NCT05139017
Lead Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions